Pfizer Inc. (PFE) Position Decreased by Capital One National Association
Capital One National Association cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 396,457 shares of the biopharmaceutical company’s stock after selling 12,440 shares during the period. Pfizer makes up approximately 1.1% of Capital One National Association’s holdings, making the stock its 13th largest position. Capital One National Association’s holdings in Pfizer were worth $13,959,000 as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. Catamount Wealth Management raised its position in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Stuart Chaussee & Associates Inc. raised its position in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the period. Financial Strategy Network LLC purchased a new position in shares of Pfizer during the first quarter valued at $205,000. Oakmont Partners LLC purchased a new position in shares of Pfizer during the second quarter valued at $211,000. Finally, Arete Wealth Advisors LLC raised its position in shares of Pfizer by 11.3% in the first quarter. Arete Wealth Advisors LLC now owns 7,172 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 726 shares during the period. 69.65% of the stock is owned by institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 0.27% during mid-day trading on Friday, hitting $33.56. The company had a trading volume of 14,819,706 shares. The stock has a 50 day moving average price of $34.29 and a 200-day moving average price of $34.19. The stock has a market capitalization of $203.56 billion, a PE ratio of 29.75 and a beta of 0.86. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.62 by $0.02. The business had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.56 EPS. On average, analysts forecast that Pfizer Inc. will post $2.46 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be paid a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 3.58%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s payout ratio is currently 95.24%.
PFE has been the subject of several research reports. Jefferies Group reissued a “buy” rating and set a $42.00 price objective (up from $41.00) on shares of Pfizer in a report on Tuesday, June 14th. Deutsche Bank AG reissued a “buy” rating on shares of Pfizer in a report on Wednesday, June 15th. Piper Jaffray Cos. reissued an “overweight” rating and set a $54.00 price objective on shares of Pfizer in a report on Monday, June 27th. Vetr raised Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price objective for the company in a report on Monday, June 27th. Finally, Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, July 20th. Ten research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.